Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Organon & Co. (OGN)

NYSE: OGN · Pharmaceutical Preparations · Jersey City, NJ

Our rating: Cautious

Cautious reaffirmed at $13.87, high conviction, November 6, 2026.

Breaks if: The Cautious call is wrong if Organon posts two consecutive quarterly revenue prints that are flat-to-growing year-over-year (0% or better) by the end of Q2 2027, while maintaining trailing-twelve-month FCF above $450M — evidence that the biosimilar and women's health segments are absorbing the patent losses faster than expected. A sustained recovery in the stock through $17.50 would signal the same re-rating and invalidate the call.

Key figures

Market value$3.6B
Revenue, last 12 months$6.1B
Net income, last 12 months$213M
Free cash flow, last 12 months$675M
Price to earnings17.1×
Free cash flow yield18.5%
Dividend yield0.6%
Operating marginn/a
Return on equity20.3%
Beta to the S&P 5000.72
Volatility, annualized55.3%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$1.6B−1.7%$0.60$326M
June 30, 2026$1.6B−2.3%$0.40$65M
March 31, 2026$1.5B−3.5%$0.55$188M
December 31, 2025$1.5B−5.3%$-0.78$96M
September 30, 2025$1.6B1.3%$0.61$218M
June 30, 2025$1.6B−0.8%$0.56$181M
March 31, 2025$1.5B−6.7%$0.33$43M
December 31, 2024$1.6B−0.4%$0.41$335M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

13 ledger entries and 17 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.